VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
NBTX
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
NBTXNanobiotix S.A.
$26.90$1.4B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. NBTX
  4. Financial Ratios

Nanobiotix S.A. (NBTX) Financial Ratios

Latest Ratios: P/E Ratio -49.0x · EV/EBITDA N/A · ROE N/A. (2011–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

NBTX Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Market Cap$1.4B$1.1B$136M$269M$128M$281M$402M————
Enterprise Value$1.4B$1.1B$137M$244M$140M$243M$332M————
P/E Ratio →-49.02——————————
P/S Ratio41.8437.30—7.4226.78106.29173.06————
P/B Ratio—————10.505.71————
P/FCF———————————
P/OCF———————————

P/E links to full P/E history page with 30-year chart

NBTX EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
EV / Revenue—38.73—6.7429.2591.97142.88————
EV / EBITDA———————————
EV / EBIT———————————
EV / FCF———————————

NBTX Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Gross Margin100.0%100.0%100.0%100.0%100.0%100.0%100.0%100.0%100.0%100.0%100.0%
Operating Margin-36.5%-36.5%951.2%-74.0%-977.8%-1986.4%-1566.8%-1841.0%-864.2%-678.9%-403.1%
Net Profit Margin-80.8%-80.8%947.6%-109.6%-1194.3%-1775.7%-1444.7%-2003.7%-872.2%-702.4%-403.6%

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
ROE—————-96.7%-98.0%-825.6%-104.3%-85.3%-132.6%
ROA-35.5%-35.5%-84.5%-51.7%-70.6%-39.9%-35.3%-99.4%-58.5%-59.5%-77.0%
ROIC——————-698.8%-1153.3%—-1099.7%-628.4%
ROCE-115.5%-115.5%-260.5%-81.3%-107.7%-58.4%-46.5%-122.4%-72.7%-71.9%-105.4%

NBTX Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Debt / Equity—————1.720.70—1.440.110.33
Debt / EBITDA———————————
Net Debt / Equity—————-1.41-1.00—-1.10-0.97-0.88
Net Debt / EBITDA———————————
Debt / FCF———————————
Interest Coverage-1.30-1.30-8.44-3.04-7.83-67.43-109.96-9.76-35.50-233.15-213.84

NBTX Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Current Ratio1.091.091.041.751.382.536.583.223.685.683.26
Quick Ratio1.091.091.041.751.302.536.583.033.586.203.87
Cash Ratio0.920.920.841.511.092.286.262.453.125.052.55
Asset Turnover—0.44-0.110.390.080.030.020.050.080.060.18
Inventory Turnover———————————
Days Sales Outstanding—94.57-433.2829.91217.20537.02608.36180.42104.6082.770.35

NBTX Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Dividend Yield———————————
Payout Ratio———————————

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Earnings Yield———————————
FCF Yield———————————
Buyback Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%————
Total Shareholder Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%————
Shares Outstanding—$48M$47M$37M$35M$35M$24M$22M$20M$17M$15M

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetStrained
Cash FlowBurning
Top Statement Risk

Milestone-dependent revenue concentration

Multiples Reflect Milestone Optionality, Not Earnings

According to the supplied market data, NBTX trades at a P/S of 46.71 and a negative trailing P/E of -54.73, a configuration that suggests investors are pricing future partner-linked milestones rather than current earnings power.

A 46.71 price-to-sales multiple against a revenue base that swings from roughly $33M to negative quarters appears to rest on expectations of future clinical success rather than on sustained revenue generation. The negative P/E is uninformative in isolation because net losses persist, so the more useful reading is that equity value depends on the NANORAY-312 readout and the durability of the Janssen relationship. Investors should monitor whether the multiple compresses as revenue normalizes, since a high P/S on lumpy partner income may not be sustainable if milestone recognition slows.

Full Gross Margin Masks Operating Losses

Based on the reported figures, NBTX shows a 100% gross margin across all ten quarters, yet its operating margin of -3.2% in 2026Q2 and net margin of -6.3% indicate that development spending absorbs the entire licensing contribution.

The uniform 100% gross margin reflects licensing economics with no reported cost of goods sold, so it carries little information about future manufacturing profitability. Operating margins have oscillated between roughly +3.0% and -19.5% without a durable inflection, which suggests earnings quality is governed by milestone timing rather than an improving cost base. Net margin deterioration to -80.8% on a TTM basis versus the quarterly figures indicates non-operating charges that warrant further investigation.

Negative Equity Constrains Refinancing Flexibility

As reported in financial statements, NBTX's debt-to-equity ratio of 25.17 in 2022Q2 and total debt of $106.6M against negative equity of -$33.4M in 2026Q2 suggest a balance sheet where liabilities materially exceed the equity cushion.

Negative shareholder equity means that any impairment or further losses directly erode a position already offset by liabilities, leaving limited margin for repayment or refinancing. Interest coverage is negative in most periods, indicating that operating income does not currently cover financing costs, which appears to heighten dependence on partner payments or equity issuance. Investors should monitor debt maturities and any covenant terms, as these are not detailed in the supplied data and their absence limits conclusions about near-term refinancing risk.

Cash Buffer Thin Against Persistent Burn

Based on EDBL-style reported figures, NBTX's current ratio of 1.44 and cash of $110.8M in 2026Q2 provide a near-term buffer, but cash has ranged from $21.6M to $83.9M across the window, indicating reliance on lumpy inflows.

The current ratio is supported by cash and deferred revenue recognition rather than by a self-funding operating model, so headline liquidity can overstate the cushion available under stress. Because the quick ratio equals the current ratio, inventory dependence is negligible, and the relevant stress test is cash runway against quarterly burn of roughly $22M to $23M in operating and free cash flow. A severe revenue pause from partners would likely compress the buffer quickly, warranting monitoring of cash balances against burn.

Revenue Growth May Overstate Commercial Traction

Based on reported figures, the 512.3% year-over-year revenue growth and 100% gross margin could be misread as commercial traction, while the swinging quarterly pattern suggests the revenue base is non-recurring and partner-dependent.

Trailing P/S and gross margin metrics are most commonly misapplied to this business model because they imply a product-sales economy that does not exist here. Gross margin is structurally uninformative under licensing revenue recognition, so the more relevant measure is operating cash burn relative to milestone timing. Investors should adjust for milestone and upfront-payment recognition and model a revenue cliff if partner payments do not recur.

Download Financial Ratios Data

Includes 30+ ratios · 15 years · Updated daily

Consensus & Technical Research Suite
Open NBTX Terminal

NBTX Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

NBTX — Frequently Asked Questions

Quick answers to the most common questions about buying NBTX stock.

What is Nanobiotix S.A.'s P/E ratio?

Nanobiotix S.A.'s current P/E ratio is -49.0x. This places it at the 50th percentile of its historical range.

Is NBTX stock overvalued?

Based on historical data, Nanobiotix S.A. is trading at a P/E of -49.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.

What are Nanobiotix S.A.'s profit margins?

Nanobiotix S.A. has 100.0% gross margin and -36.5% operating margin.